NYSE · AZN
AstraZeneca financials
$164.21−1.17%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $58.74B | $54.07B | $45.81B | $44.35B | $37.42B | $26.62B | $24.38B | $22.09B | $22.46B | $23.00B |
| Gross profit | $48.11B | $43.87B | $37.54B | $31.96B | $24.98B | $21.32B | $19.46B | $17.15B | $18.15B | $18.88B |
| Gross margin | 81.9% | 81.1% | 82.0% | 72.1% | 66.8% | 80.1% | 79.8% | 77.7% | 80.8% | 82.1% |
| Operating income | $13.36B | $9.75B | $6.85B | $3.24B | -$436.0M | $3.63B | $2.92B | $3.39B | $3.68B | $4.90B |
| Net income | $10.23B | $7.04B | $5.96B | $3.29B | $115.0M | $3.20B | $1.33B | $2.15B | $3.00B | $3.50B |
| Net margin | 17.4% | 13.0% | 13.0% | 7.4% | 0.3% | 12.0% | 5.5% | 9.8% | 13.4% | 15.2% |
| Diluted EPS | $6.54 | $4.50 | $3.81 | $2.11 | $0.08 | $2.44 | $1.03 | $1.70 | $2.37 | $2.76 |
| EBITDA | $19.09B | $16.44B | $12.24B | $8.72B | $6.09B | $6.78B | $6.69B | $7.14B | $6.71B | $7.26B |
| Operating cash flow | $14.57B | $11.86B | $10.35B | $9.81B | $5.96B | $4.80B | $2.97B | $2.62B | $3.58B | $4.14B |
| Free cash flow | $11.77B | $9.94B | $8.98B | $8.72B | $4.87B | $3.84B | $1.99B | $1.57B | $2.25B | $2.70B |
| Diluted shares | 1,562.0M | 1,563.0M | 1,562.0M | 1,560.0M | 1,427.0M | 1,313.0M | 1,301.0M | 1,267.0M | 1,267.0M | 1,266.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.71B | $5.49B | $5.84B | $6.17B | $6.33B | $7.83B |
| Short-term investments | $30.0M | $166.0M | $122.0M | $239.0M | $69.0M | $160.0M |
| Total debt | $27.82B | $28.84B | $27.49B | $28.28B | $29.79B | $19.70B |
| Total assets | $114.07B | $104.03B | $101.12B | $96.48B | $105.36B | $66.73B |
| Total liabilities | $65.36B | $63.16B | $61.95B | $59.42B | $66.08B | $51.09B |
| Shareholders' equity | $48.72B | $40.87B | $39.17B | $37.06B | $39.29B | $15.64B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology